Capsule Summary
In an attempt to better classify molecular profiles in chronic rhinosinusitis (CRS)subtypes and promote endotyping, we characterize the expression of relevant type 2 inflammatory markers in several clinical subtypes of CRS.
Objective Allergic fungal rhinosinusitis (AFRS) is a clinical subtype of chronic rhinosinusitis with nasal polyps (CRSwNP), characterized by eosinophilic mucin, evidence of fungal elements within the mucin, fungal-specific type I hypersensitivity, and characteristic computed tomography findings. It remains controversial whether AFRS represents a disease with a unique pathophysiology from chronic rhinosinusitis or is merely a severe form of CRSwNP. The goal of this study was to identify molecular features unique to AFRS. Study Design Cross-sectional case-control. Setting Single academic tertiary referral institution. Subjects and Methods Subjects included 86 patients undergoing endoscopic sinus surgery: CRSwNP (n = 34), AFRS (n = 37), and healthy controls (n = 15). Pathway and correlation analyses were performed with whole-genome microarray data for study patients undergoing surgery for recalcitrant chronic rhinosinusitis. Our findings were confirmed with quantitative polymerase chain reaction and immunohistochemical studies. Results AFRS was uniquely characterized by a pronounced association with adaptive T helper 2-associated immune gene expression. AFRS exhibited altered expression of proteins associated with secretory salivary peptides-namely, histatin, a peptide with known antifungal activity in the oral cavity. Furthermore, the expression of histatins correlated negatively with that of type 2 inflammatory mediators. We confirm the decreased expression of histatins in AFRS when compared with CRSwNP by quantitative polymerase chain reaction and localized its expression to a submucosal cell population. Conclusion There exist clear molecular profiles that distinguish AFRS from CRSwNP. This divergence translates into an altered ability to control fungal growth and may in part explain some of the phenotypical differences between CRSwNP and AFRS.
Objective
In the pathophysiology of chronic rhinosinusitis with nasal polyps (CRSwNP), Aspergillus fumigatus (A. fumigatus) can upregulate IL‐33 from human sinonasal epithelial cells (SNECs), which then activates innate lymphoid cells causing release of IL‐13, an important driver of allergic inflammation. However, the mechanism by which A. fumigatus mediates the induction of IL‐33 expression remains to be elucidated. The objectives of this study were to determine the specific fungal component(s) and the receptor responsible for mediating the A. fumigatus induced increase in IL‐33 expression in SNECs from patients with CRSwNP.
Methods
SNECs from CRSwNP patients were cultured and stimulated with various fungal components in the absence or presence of 4‐(2‐Aminoethyl)benzenesulfonyl fluoride hydrochloride, an irreversible serine protease inhibitor, or GB83, a reversible protease activated receptor 2 (PAR2) inhibitor. IL‐33 expression was evaluated using quantitative real‐time polymerase chain reaction (qRT‐PCR). PAR2 expression was examined in inflamed mucosa from nonatopic control and CRSwNP patients.
Results
Elevation of IL‐33 expression in primary SNECs was found in response to fungal protease but not fungal cell wall components. PAR2 expression was elevated in inflamed mucosa from CRSwNP patients in comparison to controls. The A. fumigatus fungal protease‐mediated elevation in IL‐33 expression by human SNECs was serine protease‐ and PAR2‐dependent.
Conclusion
These data suggest that serine protease activity of A. fumigatus is capable of inducing IL‐33 expression in CRSwNP SNECs via PAR2, a potential therapeutic target in the treatment of CRSwNP.
Level of Evidence
NA
Laryngoscope, 129:2230–2235, 2019
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.